Browsing: Acute Lymphoblastic Leukemia
Eosinophilia is a highly variable disease that can be relatively mild or potentially fatal; it can occur due to primary…
Systemic mastocytosis, though a rare disease, is more common than clinicians may think and diagnosis of the condition can often…
Myeloproliferative Neoplasms (MPNs) carry a risk of complications, such as thrombosis; the degree of risk is influenced in part by…
It is well known that studying larger patient groups produces more robust results in research. Omar Abdel-Wahab, MD, from the…
It is known that spliceosome gene mutations can drive hematological cancers, but there may also be neomorphic mutations at play.…
There is often a lack of communication about the strong evidence linking lifestyle to cancer risk. In this video, Annie…
“Health service personnel are paramount in endorsing and conveying lifestyle messages that reduce the risk of cancer in the public.…
There is extensive and durable evidence supporting the link between lifestyle and cancer recurrence, yet this evidence is not being…
“Lifestyle intervention trials rely heavily on cooperation from the patient group and thus, it is important to effectively engage these…
“As a greater number of people are surviving cancer, this is an exciting time to determine the magnitude of effect…
Dr. Jack West reviews the pros and cons of using osimertinib first line vs. “saving” it as a second line…
Innovative research has begun to create a novel therapy that could potentially treat a variety of malignancies, including acute myeloid…
As research into the different aspects of treating leukemia develops there will be an increase in the number of targeted…
This is an exciting time for acute myeloid leukemia (AML), with the introduction of numerous novel combination therapies and the…
Currently, the majority of therapeutics that target splicing mutations in hematological malignancies are in the early or pre-clinical phases. In…
Mutations can change the function of a protein and thus be the driver of diseases. In this video, Omar Abdel-Wahab,…
Patient advocacy groups can be of great use to patients, giving them means to network with other patients and providing…
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) increasingly appear to be influenced by genetic features, with new research attempting…
In recent years, the medical community has become aware of certain genetic factors that can predispose someone to developing hematological…
Using kinase inhibitors, such as midostaurin, to treat acute myeloid leukemia typically only produces a partial response. Mark Levis, MD,…
The BCL2 inhibitor venetoclax has shown remarkable response rates in elderly acute myeloid leukemia (AML) patients when used in combination…
“In this insightful interview, Mark Levis, MD, PhD, from The Johns Hopkins Hospital, Baltimore, MD, talks about the four primary…
Acute myeloid leukemia (AML) is no longer thought to be just a single disease; thus, each subtype needs to be…
It is still early days for immunotherapeutic strategies. Speaking from the International Conference on Acute Myeloid Leukemia 2017, Estoril, Portugal…
Cancers, such as myeloproliferative neoplasms (MPNs), evolve from repeated mutations; it is unlikely that one mutation alone causes cancer. In…
The discovery of various molecular risk factors for myeloproliferative neoplasms (MPNs) has revolutionized the way in which doctors diagnose these…
Nurses provide a high level of contact to a patient with cancer, which is essential in order to educate them…
An acute oncology service works to manage the unexpected care needs of patients with cancer. In this interview, recorded at…
The use of immunotherapy in the UK as a treatment for cancer has increased over the past decade. In this…
Clinical Nurse Specialists (CNSs) play a key role for a cancer patient, in both performing clinical procedures, and offering psychological…
Conferences can be a fantastic opportunity to network within a certain profession, and get an idea of the challenges that…
Nurses in the UK are highly valued as part of the multidisciplinary health team. However, as Daniel Kelly, PhD, from…
Specialist cancer nurses play a vital role in improving patient care, in both clinical and psychological contexts. In this interview,…
The current baseline imaging technology for multiple myeloma (MM) management includes PET and MRI. In this interview, Ravi Vij, MD,…
Radiological advances are now enabling us to decipher the disease biology of multiple myeloma (MM) in ways that were previously…
There are two new highly promising classes of treatments for multiple myeloma. Speaking from the Myeloma 2017 meeting in Edinburgh,…
Within multiple myeloma (MM), there are biologically different diseases that are distinctly characterized. In this video, Gareth Morgan, MD, FRCP,…
There has been a genome-wide initiative to identify the copy number variants and mutational drivers of multiple myeloma. In this…
Dr. Jack West reviews the results of the ARCHER-1050 trial that showed superior efficacy with dacomitinib vs. gefitinib in EGFR…
A full understanding of the methods available for diagnosis, prognosis and stratification are required in order to choose the optimal…
Although there is a lot of hope and optimism surrounding immunotherapy, Marion Subklewe, MD, of the University of Munich, Munich,…
Cinical trials for acute myeloid leukemia (AML) typically only include relapsed/refractory patients, rather than patients at an earlier stages of…
The use of T-cell engaging antibodies for acute myeloid leukemia (AML) treatment is in the very early stages. In this…
Many variables are involved in selecting the type of treatment that a patient can receive. Speaking from the International Conference…
The widespread accessing of new drugs by HCPs and patients can be a very long process. Currently, venetoclax is in…
“This is an exciting time for new acute myeloid leukemia (AML) therapies, particularly combination treatments. In this video, Marina Konopleva,…
“In this exciting interview, Marina Konopleva, MD, PhD of the MD Anderson Cancer Center, Houston, TX, provides optimistic preliminary results…
Compassion and understanding are two key components within medical care. At the International Conference of Acute Myeloid Leukaemia 2017 in…
New research methods enable a greater understanding of a disease and allow for more personalized medicine to be produced. In…